Shoulder Innovations, Inc.
HealthcareNYSE:SI · New York Stock Exchange
-$0.06 today
Vol 0.07M · Avg 0.10M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-26.0%
avg -47.1%
ROIC
-14.8%
avg -25.9%
ROA
-23.8%
avg -27.8%
Analysis
ROIC is currently the strongest return metric at -14.8% versus its period average of -25.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Alan J. Lane | Chief Executive Officer & Director | $1.06M | — | 64 | $1,084.00 | <0.01% |
Kathleen Fraher | Executive Vice President & Chief Risk Officer | $623,544.00 | — | 48 | $12,571.00 | 0.06% |
Benjamin C. Reynolds | Pres | $614,029.00 | — | 48 | $359.00 | <0.01% |
Judith Knowles | Sec. | — | — | — | — | — |
Elaine Batlis | Executive Vice President & Mang. of Warehouse Lending Division | — | — | 71 | — | — |
Alaric Eby | Chief Product Devel. Officer | — | — | — | — | — |
Antonio R. Martino | Chief Financial Officer | — | — | 58 | $6,442.00 | 0.03% |
John Bonino | Chief Legal Officer | — | — | 77 | $30,987.00 | 0.15% |
Hunter Stenback | Head of Investor Relations | — | — | — | — | — |
Son-Jai Paik | Chief HR Officer | — | — | 53 | $479.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$214,873.03
Sells
0
$0.00
Net Sentiment
+$214,873.03
Net buying
Most Active
Points Jeffrey S.
3 transactions
Analysis
Insiders reported 7 buys worth $214,873.03 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $214,873.03. Points Jeffrey S. was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +30.9% (3yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +30.9% (3yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$364.90M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Inogen, Inc.
NASDAQ:INGN
$173.28M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Nano-X Imaging Ltd.
NASDAQ:NNOX
$122.48M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
Outset Medical, Inc.
NASDAQ:OM
$83.23M
MDxHealth S.A.
MDXH
$27.85M
Who manages SI?
Shoulder Innovations, Inc. (SI) lists 10 active executives. The top listed executive is Judith Knowles, Sec..
Are SI insiders buying or selling?
Recent insider activity shows net selling of $10.31M.
Explore More
Continue the stock analysis
Jump to another research area for this company.